The company's lead asset, IMVT-1402, is a next-generation neonatal FcRn inhibitor advancing in up to six potentially registrational trials for major autoimmune diseases like Graves' disease and Myasthenia Gravis. The company maintains a war chest of $4.4 billion in cash and cash equivalents as of September 2025, giving it a long runway to execute its development strategy.
Cyborg Score Rationale
Immunovant combines deep clinical expertise in FcRn technology, a richly funded cash position, and a multi-indication pipeline for blockbuster-potential assets. However, as a pre-commercial clinical-stage company, it faces significant execution risk with no approved products and high R&D burn.
Top Insights
Lead asset IMVT-1402 targets six major autoimmune indications with high unmet medical needs
Company maintains exceptional liquidity with $4.4B cash as of Q3 2025, sufficient for multi-year pipeline execution
Subsidiary of Roivant Sciences Ltd. (55.45% ownership), providing financial and strategic backing
Pre-commercial stage with zero revenue but $360.9M R&D spend in FY 2025, indicating aggressive development velocity
Named Competitors
Efgartigimod — FcRn inhibitor monoclonal antibody for autoimmune diseases
Pegcetacoplan — Complement inhibitor for autoimmune and blood disorders
Various biologics — Established players in immunology and autoimmune treatment
Recent Developments
(November 2025) Market capitalization reached approximately $4.26 billion based on strong investor confidence in pipeline potential
(September 2025) Company reported $4.4 billion in cash and cash equivalents, ensuring multi-year funding runway
(FY 2025) High R&D intensity with $360.9 million in research spending to advance registrational trials across six indications
Open the full interactive Immunovant, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.